期刊文献+

纳米粒子的靶向作用机制研究进展 被引量:4

Progress in the mechanism of targeting of nanoparticles
下载PDF
导出
摘要   纳米粒子是指尺度在1 ~ 100nm 之间的微粒[1],这类粒子具有量子尺寸效应、小尺寸效应、表面与界面效应与协同效应等性质,表现为比表面积大、表面活性中心多、表面反应活性高、吸附能力强、催化能力高、毒性低及不易被体内和细胞内各种酶降解等.纳米粒子载药不仅可以提高药物对癌组织的靶向性,还可以高选择性地作用于癌细胞内外的小分子或基因物质,对原发恶性肿瘤和转移性恶性肿瘤都有很好的疗效[2-4].……
出处 《中国医药生物技术》 CSCD 2007年第5期370-372,共3页 Chinese Medicinal Biotechnology
基金 国家高技术研究发展计划(863计划)(2006AA03Z333) 国家重点基础研究计划(973计划)(2006CB933304)
  • 相关文献

参考文献21

  • 1[2]Shikata F,Tokumistu H,Ichikawa H,et al.In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer.Eur J Pharm Biopharm,2002,53(1):57-63.
  • 2[3]Harisinghani MG,Barentsz J,Hahn PF,et al.Noninvasive detection of clinically occult lymph-node metastases in ptostate cancer.N Engl J Med,2003,348(25):2491-2499.
  • 3[4]Tamura T,Fujita F,Tanimoto M,et al.Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice.J Control Release,2002,80(1-3):295-307.
  • 4[5]Khandare J,Minko T.Polymer-drug conjugates:progress in polymeric prodrugs.Prog Polym Sci,2006,31(4):359-397.
  • 5[6]Moghimi SM,Hunter AC.Poloxamers and poloxamines in nanoparticle engineering and experimental medicine.Trends Biotechnol,2000,18(10):412-420.
  • 6[7]Maeda H.The enhanced permeability and retention (EPR) effect in tumor vasculature:the key role of tumor-selective macromolecular drug targeting.Adv Enzyme Regul,2001,41:189-207.
  • 7[8]David A,Kopecková P,Minko T,et al.Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.Eur J Cancer,2004,40(1):148-157.
  • 8[9]Modi S,Prakash Jain J,Domb AJ,et al.Exploting EPR in plomer drug conjugate delivery for tumor targeting.Curr Pharm Des,2006,12(36):4785-4796.
  • 9[10]Chau Y,Padera RF,Dang NM,et al.Antitumor efficacy of a noval polymer-peptide-drug conjugate in human tumor xenograft models.Int J Cancer,2006,118(6):1519-1526.
  • 10[11]Chau Y,Dang NM,Tan FE,et al.Investigation of targeting mechanism of new dextrom-peptide-methotrexate conjuagetes using biodistribution study in matrix-metalloproteinase-overexpressing tumer xenograft model.J Pharm Sci,2006,95(3):542-551.

同被引文献27

  • 1梅林,孙洪范,宋存先.紫杉醇制剂研究进展[J].中国药学杂志,2006,41(18):1366-1370. 被引量:16
  • 2王培林,傅松滨.医学遗传学[M].第3版,北京:科学出版社,2011:108-153.
  • 3LU J Q,HUANG Y X,ZHAO W C,et al.PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel tobreast and prostate cancers[J].Biornaterials,2013,34:1591-1600.
  • 4Koci L, Chlebova K, Hyzdalova M , et al. Apoptosis inhibitor 5(API-5; AAC-11 ; FIF) is up-regulated in human carcinomas invivo[J]. Oncol Lett, 2012,3(4) : 913-916.
  • 5Wang Y, Lee AT, Ma JZ, et al. Profiling microRNA expression inhepatocellular carcinoma reveals microRNA-224 Up-regulation andapoptosis inhibitor-5 as a microRNA-224-specific target [ J ]. J BiolChem,2008,283(19) : 13205-13215.
  • 6Zhang Y,Takahashi S,Tasaka A,et al. Involvement of microRNA-224 in cell proliferation,migration,invasion,and anti-apoptosis inhepatocellular carcinoma [ J ]. J Gastroenterol Hepatol,2013,28(3):565-575.
  • 7in hepatocellular carcinoma through epigenetic mechanisms [ J ].FASEB J, 2012, 26(7) :3032-3041.
  • 8Aghajanian C,Soignet S, Dizon DS. A phase I trial of the novelproteasome inhibitor PS34 1 in advanced solid tumor malignancies[J]. Clin Cancer Res ,2002 ,8 ( 8) :2505-2511.
  • 9Rigou P, Piddubnyak V,Faye A, et al. The antiapoptotic proteinAAC-11 interacts with and regulates Acinus-mediated DNAfragmentation[J]. EMBO J,2009, 28(11 ):1576-1588.
  • 10Yu Wang,Han Chong Toh,Pierce Chow,Alexander Y. F. Chung,David J. Meyers,Philip A. Cole,London L. P. J. Ooi,Caroline G. L. Lee.MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms[J]. The FASEB Journal . 2012 (7)

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部